Hip osteoarthritis affects millions of people and can make everyday activities painful. As regenerative treatments grow in popularity, patients increasingly ask whether stem cell therapy or PRP can help the hip. This article reviews the most recent 2025 and 2026 evidence for cell-based and PRP treatments for hip osteoarthritis, and what it realistically means for someone considering care in Honolulu.
30-50%
typical short-term pain reduction reported for hip stem cell studies
0
stem cell products FDA-approved for hip osteoarthritis
5
clinical providers on the team
The hip is a large, weight-bearing joint, and osteoarthritis there can limit walking, climbing stairs, and sleep. Because the hip sits deep in the body, injections are more involved than a knee, and the evidence has to be read carefully. Recent reviews give a clearer picture than ever of what these treatments can and cannot do for the hip.
A 2025 scoping review of stem cell therapies for hip osteoarthritis found consistent short-term pain reduction and functional gains, with studies reporting meaningful improvements in pain scores and hip function. A separate 2025 study of intra-articular adipose-derived stem cells in 168 hips reported clinical improvement over six months, with moderate arthritis and female sex associated with better results. The honest caveat is that evidence for lasting structural cartilage repair is limited, and no stem cell product is FDA-approved for hip osteoarthritis.
“A 2025 scoping review of stem cell therapies for hip osteoarthritis found consistent short-term pain reduction and functional gains, though durable evidence of cartilage repair remains limited.”
For PRP, a 2025 double-blind randomized trial found it at least as effective as hyaluronic acid for hip osteoarthritis pain, and notably better at reducing pain in hips affected by developmental dysplasia. Overall, PRP in hip osteoarthritis shows short-term pain and function benefits, while durable structural benefit is not yet established. As with all regenerative care, the expectation should be symptom support and function, not a guaranteed reversal of arthritis.
The recent research supports regenerative treatments for the hip as a reasonable option for many patients seeking relief, but it also keeps expectations honest: benefits are often short-term, results vary, and none of these treatments are FDA-approved for the condition. The right first step is a careful evaluation of your imaging and symptoms to confirm the pain is really coming from the hip joint, and to decide whether an injection, rehabilitation, weight management, or a combination is the best fit.
A note from the clinic
Hip pain deserves a thorough diagnosis before any injection. At Aloha Stem Cell in Honolulu we take the time to understand what is really driving your discomfort and recommend the path that fits you, even when that path is not an injection. Call (808) 593-2525 to book a low-pressure consultation.
Our team is happy to listen to your story, answer your questions, and help you decide whether a consultation makes sense. There is no pressure and no obligation.
Keep reading
The FDA now lists Regenecyte, a cord blood stem cell product, among approved cellular therapies. It is a real milestone for blood stem cell transplant patients, and it is not a treatment for joint pain. Here is what the approval is, what it is not, and why it matters when you read stem cell news.
In September 2026 the FDA granted Fast Track status to an experimental cell therapy for ALS, and in August researchers presented new Phase 1/2 data on a stem cell therapy for Parkinson's. Both are real advances and both remain investigational. Here is the honest read.
A stem cell-derived islet therapy restored insulin production in early trials, with 10 of 12 patients insulin-independent at one year. Here is what the 2025-2026 results show, what the FDA has and has not done, and what it means for people with diabetes.
Book a consultation
Pick a time that works for you and our team will confirm your consultation. Questions first? Call us anytime at (808) 593-2525.